| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
METHOD |
Rosetta Inpharmatics, A wholly owned subsidiary of Merck & Co., Inc., Seattle, Washington 98109, USA
Reprint requests to: Christopher K. Raymond, Rosetta Inpharmatics, 401 Terry Avenue N, Seattle, WA 98109, USA; e-mail: christopher_raymond{at}merck.com; fax: (206) 802-6411.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONRESULTS AND DISCUSSIONCONCLUSIONSMATERIALS AND METHODSREFERENCES |
|---|
Keywords: primer extension; quantitative PCR; locked nucleic acid; microRNA; siRNA; SYBR green
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTS AND DISCUSSIONCONCLUSIONSMATERIALS AND METHODSREFERENCES |
|---|
). Short-interfering RNAs (siR-NAs) are derived from double-stranded RNA molecules (Tomari and Zamore 2005). Both are processed into ~21-nucleotide (nt), single-stranded molecules that become incorporated into the RNA-induced silencing complex (RISC) (Liu et al. 2004; Song et al. 2004). RISC mediates down-regulation of gene expression through translational inhibition, transcript cleavage, or both (Tang 2005). RISC is also implicated in transcriptional silencing in the nucleus of a wide range of eukaryotes (Morris et al. 2004; Matzke and Birchler 2005).
Analytical tools for monitoring nucleic acids are an indispensable part of molecular biology. Several groups have described microarray methods for monitoring microRNA expression (Babak et al. 2004; Barad et al. 2004; Miska et al. 2004; Nelson et al. 2004; Sempere et al. 2004; Sun et al. 2004; Thomson et al. 2004). These efforts have provided a qualitative overview of microRNA expression patterns in cell lines and in normal and diseased human tissues (Babak et al. 2004; Baskerville and Bartel 2005). With gene expression microarrays, quantitative, transcript-specific PCR assays have proven to be a powerful complementary tool for validating initial observations and for extending data for transcript regions that are not addressed by probes on the array. In an analogous manner, we sought to create a quantitative assay for miRNAs that would allow us to assess absolute copy (Lagos-Quintana et al. 2003; Lim et al. 2005) numbers and a flexible assay for siRNAs that would allow us to measure any engineered interfering sequence. Several detection methods have been reported in the literature, including Northern blots (Lagos-Quintana et al. 2003; Lim et al. 2005), primer extension (Zeng and Cullen 2003), Invader Assay (Allawi et al. 2004), signal-amplifying ribozymes (Hartig et al. 2004), and mirMASA bead-based technologies (Babak et al. 2004). None of these approaches could be easily implemented in our laboratory, so we sought to construct an assay method by combining existing molecular biology techniques.
The research of Zeng and Cullen (2003) demonstrated that primer extension (PE) was a viable method for quantitative analysis of microRNA expression. Rather than using radioactive band-shift assays, we wished to detect primer-extended products by quantitative PCR (qPCR). The short length of miRNAs and siRNAs presents a unique challenge in PCR design. Most conventional PCR primers are similar in length to interfering RNAs, implying that very short primers would be required for assay design. Locked nucleic acids (LNA) possess a 2'-O,4'-C methylene bridge in the ribose moiety of nucleotide (Petersen and Wengel 2003). The modification stabilizes the conformation of the sugar group and thereby increases the hybridization affinity of oligonucleotides that contain LNA bases. These nucleotide analogs are an integral part of PCR primers used in the assay. We also conducted a systematic survey of sequence length requirements necessary for sequence-specific PE. Oligonucleotides that were 10–12 nt in length promoted highly efficient PE cDNA synthesis from miRNA templates. Lastly, Schmittgen et al. (2004) report a qPCR method for monitoring of microRNA precursors that relies on SYBR green detection of short amplicons. We combined PE cDNA synthesis, LNA-containing short PCR primers, and SYBR green qPCR to develop the primer-extension, quantitative PCR (PE-qPCR) method described here.
|
RESULTS AND DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTS AND DISCUSSIONCONCLUSIONSMATERIALS AND METHODSREFERENCES |
|---|
). In the first step, a tailed, gene-specific primer (GS primer) was used (1) to convert the RNA template into cDNA; (2) to introduce a "universal" PCR binding site to one end of the cDNA molecule; and (3) to extend the length of the cDNA to facilitate subsequent monitoring by qPCR. In the second step, the resulting primer-extended, full-length cDNA was quantified by real-time PCR using a combination of an LNA-containing, miRNA/siRNA-specific "reverse" primer (LNA-R primer) and a generic universal primer common to all assays. Amplification of this chimeric cDNA was monitored in the real-time qPCR reaction by SYBR green fluorescence.
|
). First, "sensitivity" was defined as the cycle threshold (CT) value at which an assay containing 200 pM of synthetic miRNA was detected. The lower this CT value, the more "sensitive" was the assay. Second, "dynamic range" was defined as the CT difference between a 200-pM template spike-in (signal) and a no-template control (background). Assays with a high dynamic range allow measurements of very low miRNA/siRNA copy numbers.
Assay optimization
The success of the PE-qPCR method was critically dependent on short, ~15-nt LNA-R primers. Two or three LNA bases were substituted into each LNA-R primer within the first 8 nt from the 5' end of the oligonucleotide (Table 1). The LNA bases were always separated by at least 1 nt, the substitutions selected were those that raised the predicted Tm by the highest amount, and the final predicted Tm of the selected primers were specified to be 
55° C.
|
). In almost every case, LNA substitutions increased the performance of the assays. In 8/30 cases (27%), LNA bases had little or no impact on assay characteristics (Fig. 2A), in 9/30 assays (30%), LNA bases significantly enhanced assay performance (Fig. 2B,C), and in 13/30 experiments (43%), LNA bases were absolutely required (Fig. 2D). In no case did LNA base substitutions negatively impact assay performance.
|
). To minimize background, GS primers with serial 1-nt deletions were analyzed; a representative series is shown in Figure 3A. Trimming GS primers from 14 to 11 nt had little effect on signal, while increasing dynamic range (by increasing background CT values) substantially. These data motivated an exploration of the minimum sequence requirements for efficient PE-mediated cDNA synthesis (Fig. 3B). To our surprise, we found very little change in assay performance as GS priming sequences were reduced in length from 12 nt to 7 nt. Assay sensitivity decreased sharply, however, for priming sequences 6 nt. We currently use GS-priming sequences in the range of 10–12 nt, regardless of base composition.
|
). GS priming sequences of 8 nt were used along with sequence-specific LNA-R primers to explore assay specificity among these related miRNAs (Fig. 4B). Every assay tested exhibited substantial target sequence specificity, and significant "cross talk" detection of other let-7 family members was encountered in only a few cases. The series of let-7 paralog-specific assays was applied to five human tissue RNA samples (Fig. 4C). Substantial expression of let-7a and let-7f and modest expression of let-7i were observed in these five tissues.
|
). In two cases, a well-behaved assay was recovered. Taken together, these data suggest that most miRNA/siRNA sequences can be monitored using the method we describe.
Expression profiles of miRNAs
One application of the PE-qPCR technique described here is quantitative analysis of miRNA expression patterns. Assay calibration was performed using the standard curve PCR method to calibrate assay data (Raymond et al. 2004). For standard curves, it was found that DNA oligonucleotides yield CT values that are identical to or 1–2 CT values lower than RNA oligonucleotides. The slopes of DNA and RNA standard curves are identical. Because RNA oligonucleotides are rather expensive and frequently contaminated with impurities, DNA standards were used. This practice results in highly accurate relative measurements between samples, but it may lead to an underestimation of absolute expression levels.
In Figure 5, expression profiles for six miRNAs across 12 tissues are shown. The data are presented in units of miRNA copies per 10 pg of total RNA. These units were chosen since human cell lines typically yield 10 pg of total RNA per cell. Hence the data shown are rough estimates of miRNA copies per cell. As reported previously, very high levels of striated muscle-specific expression were found for miR-1, liver expression for miR-122, and brain expression for miR-124 (Lagos-Quintana et al. 2003). Quantitative analysis reveals that these microRNAs are present at tens to hundreds of thousands of copies per cell, and are in agreement with quantitative Northern blot estimates of miR-1 and miR124 levels (Lim et al. 2005). These data underscore the fact that microRNAs are among the most abundant RNAs present in cells. Consistent with previous findings (Baskerville and Bartel 2005), miR-150 was highly expressed in the immune-related lymph node, thymus, and spleen samples, while miR-24 and miR-148b showed more constitutive levels of expression, being expressed at high and low levels, respectively, in the tissues examined.
|
to generate standard curve data of the synthetic precursor species and to measure the levels of precursor present in human tissue total RNAs (Fig. 5, inset). Consistent with the pattern of mature miR-124 expression, the precursor species was only detected in brain, and the data indicate that the steady-state level of precursor species is ~3% that of the mature form. These data compare favorably with the qualitative results of Northern blots (Lagos-Quintana et al. 2003). The precursor form of miR-124 was poorly detected by the mature micro-RNA assay for miR-124. Equivalent molar amounts of mature and precursor miR-124 species were measured using primers specific for mature miR-124. The precursor molecule was detected ~2000-fold less efficiently than the mature form. Similar data were observed for two precursor species of miR-24, pre-miR-24–1 and pre-miR-24-2 (data not shown). Taken together, these data suggest that the microRNA PE-qPCR method we describe preferentially detects mature microRNAs. |
CONCLUSIONS |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTS AND DISCUSSIONCONCLUSIONSMATERIALS AND METHODSREFERENCES |
|---|
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTS AND DISCUSSIONCONCLUSIONSMATERIALS AND METHODSREFERENCES |
|---|
) were purchased from Proligo LCC. MicroRNA precursor molecules were produced by in vitro transcription using the MessageMuter shRNA production kit from Epicentre. SuperScript III reverse transcription kits (InVitrogen Corp.) were used to convert miRNAs and siRNAs into cDNAs. For reverse transcription, 6 µL of RT master mix (2 µL of water, 2 µL 5x buffer, 0.5 µL of 0.1 M DTT, 0.5 µL of 10 mM dNTPs (InVitrogen), 0.5 µL of RNAse OUT (InVitrogen), and 0.5 µL of SuperScript III enzyme) were combined with 2 µL of 0.5 µM GS primer and 2 µL of template in a 96-well plate. For detection of precursor microRNA species, siRNA duplexes or shRNA hairpins, the GS primer, and template were premixed, heated at 85° C for 2 min, snap-chilled on ice, and RT premix was added. This step was found to be unnecessary for optimal detection of microRNAs. Hairpin duplexes containing an siRNA duplex joined by a 4-nt or 9-nt loop sequence were detected at 3–6 CT higher values than siRNA duplexes or single-stranded synthetic templates even with an initial denaturation step (data not shown). The 10 µL RT reaction was incubated at 50° C for 30 min, 85° C for 5 min, cooled to room temperature, and diluted 10-fold with 90 µL of TE (10 mM Tris at pH 7.6, 0.1 mM EDTA). Standard curve dilutions of synthetic oligonucleotides ranging from 10 nM to 10 fM were performed in TE that contained 100 ng/µL of total yeast RNA (Ambion, Inc.). For quantitative analysis of samples, 0.5 µg of First Choice total RNA (Ambion, Inc.) was assayed per 10 µL RT reaction. Following reverse transcription, quadruplicate measurements of 2 µL of cDNA were made in 10 µL final reaction volumes by qPCR in a 384-well optical PCR plate using a 7900 HT PCR instrument (Applied Biosystems). SYBR green PCR mix contained 5 µL of 2x SYBR green PCR master mix (Applied Biosystems), 1.4 µL of water, 0.8 µL of 10 µM universal primer, 0.8 µL of 10 µM LNA-R primer, and 2 µL of sample. qPCR was performed using the manufacturer’s recommended conditions and dissociation curves were typically generated post-run for analysis of amplicon species (data not shown). Following PCR, the results table was exported to Excel (Microsoft Corp.), standard curves were generated, and quantitative analysis for samples was regressed from the raw data.
|
ACKNOWLEDGMENTS |
|---|
|
Footnotes |
|---|
Received June 28, 2005; accepted August 29, 2005.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTS AND DISCUSSIONCONCLUSIONSMATERIALS AND METHODSREFERENCES |
|---|
Allawi, H.T., Dahlberg, J.E., Olson, S., Lund, E., Olson, M., Ma, W.P., Takova, T., Neri, B.P., and Lyamichev, V.I. 2004. Quantitation of microRNAs using a modified Invader assay. RNA 10: 1153–1161.
Babak, T., Zhang, W., Morris, Q., Blencowe, B.J., and Hughes, T.R. 2004. Probing microRNAs with microarrays: Tissue specificity and functional inference. RNA 10: 1813–1819.
Barad, O., Meiri, E., Avniel, A., Aharonov, R., Barzilai, A., Bentwich, I., Einav, U., Gilad, S., Hurban, P., Karov, Y., et al. 2004. MicroRNA expression detected by oligonucleotide microarrays: System establishment and expression profiling in human tissues. Genome Res. 14: 2486–2494.
Bartel, D.P. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281–297.[CrossRef][Medline]
Baskerville, S. and Bartel, D.P. 2005. Microarray profiling of micro- RNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 11: 241–247.
Hartig, J.S., Grune, I., Najafi-Shoushtari, S.H., and Famulok, M. 2004. Sequence-specific detection of MicroRNAs by signal-amplifying ribozymes. J. Am. Chem. Soc. 126: 722–723.[CrossRef][Medline]
Lagos-Quintana, M., Rauhut, R., Meyer, J., Borkhardt, A., and Tuschl, T. 2003. New microRNAs from mouse and human. RNA 9: 175– 179.
Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S., and Johnson, J.M. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769–773.[CrossRef][Medline]
Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson, J.M., Song, J.J., Hammond, S.M., Joshua-Tor, L., and Hannon, G.J. 2004. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437–1441.
Matzke, M.A. and Birchler, J.A. 2005. RNAi-mediated pathways in the nucleus. Nat. Rev. Genet. 6: 24–35.[CrossRef][Medline]
Miska, E.A., Alvarez-Saavedra, E., Townsend, M., Yoshii, A., Sestan, N., Rakic, P., Constantine-Paton, M., and Horvitz, H.R. 2004. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 5: R68.[CrossRef][Medline]
Morris, K.V., Chan, S.W., Jacobsen, S.E., and Looney, D.J. 2004. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305: 1289–1292.
Nelson, P.T., Baldwin, D.A., Scearce, L.M., Oberholtzer, J.C., Tobias, J.W., and Mourelatos, Z. 2004. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat. Methods 1: 155– 161.[CrossRef][Medline]
Petersen, M. and Wengel, J. 2003. LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol. 21: 74–81.[CrossRef][Medline]
Raymond, C.K., Castle, J., Garrett-Engele, P., Armour, C.D., Kan, Z., Tsinoremas, N., and Johnson, J.M. 2004. Expression of alternatively spliced sodium channel 
-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. J. Biol. Chem. 279: 46234–46241.
Schmittgen, T.D., Jiang, J., Liu, Q., and Yang, L. 2004. A high-throughput method to monitor the expression of microRNA pre-cursors. Nucleic Acids Res. 32: e43.
Sempere, L.F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., and Ambros, V. 2004. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 5: R13.[CrossRef][Medline]
Song, J.J., Smith, S.K., Hannon, G.J., and Joshua-Tor, L. 2004. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 305: 1434–1437.
Sun, Y., Koo, S., White, N., Peralta, E., Esau, C., Dean, N.M., and Perera, R.J. 2004. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32: e188.
Tang, G. 2005. siRNA and miRNA: An insight into RISCs. Trends Biochem. Sci. 30: 106–114.[CrossRef][Medline]
Thomson, J.M., Parker, J., Perou, C.M., and Hammond, S.M. 2004. A custom microarray platform for analysis of microRNA gene expression. Nat. Methods 1: 47–53.[CrossRef][Medline]
Tomari, Y. and Zamore, P.D. 2005. Perspective: Machines for RNAi. Genes & Dev. 19: 517–529.
Zeng, Y. and Cullen, B.R. 2003. Sequence requirements for micro RNA processing and function in human cells. RNA 9: 112–123.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Ivanovska, A. S. Ball, R. L. Diaz, J. F. Magnus, M. Kibukawa, J. M. Schelter, S. V. Kobayashi, L. Lim, J. Burchard, A. L. Jackson, et al. MicroRNAs in the miR-106b Family Regulate p21/CDKN1A and Promote Cell Cycle Progression Mol. Cell. Biol., April 1, 2008; 28(7): 2167 - 2174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mathonnet, M. R. Fabian, Y. V. Svitkin, A. Parsyan, L. Huck, T. Murata, S. Biffo, W. C. Merrick, E. Darzynkiewicz, R. S. Pillai, et al. MicroRNA Inhibition of Translation Initiation in Vitro by Targeting the Cap-Binding Complex eIF4F Science, September 21, 2007; 317(5845): 1764 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, J. E. Dahlberg, and W. Tam MicroRNAs in Tumorigenesis: A Primer Am. J. Pathol., September 1, 2007; 171(3): 728 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fulci, S. Chiaretti, M. Goldoni, G. Azzalin, N. Carucci, S. Tavolaro, L. Castellano, A. Magrelli, F. Citarella, M. Messina, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia Blood, June 1, 2007; 109(11): 4944 - 4951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhang, Y. Peng, W. Wang, and B. Su Rapid evolution of an X-linked microRNA cluster in primates Genome Res., May 1, 2007; 17(5): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Beuvink, F. A. Kolb, W. Budach, A. Garnier, J. Lange, F. Natt, U. Dengler, J. Hall, W. Filipowicz, and J. Weiler A novel microarray approach reveals new tissue-specific signatures of known and predicted mammalian microRNAs Nucleic Acids Res., April 1, 2007; 35(7): e52 - e52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Linsley, J. Schelter, J. Burchard, M. Kibukawa, M. M. Martin, S. R. Bartz, J. M. Johnson, J. M. Cummins, C. K. Raymond, H. Dai, et al. Transcripts Targeted by the MicroRNA-16 Family Cooperatively Regulate Cell Cycle Progression Mol. Cell. Biol., March 15, 2007; 27(6): 2240 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kato, J. Zhang, M. Wang, L. Lanting, H. Yuan, J. J. Rossi, and R. Natarajan MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors PNAS, February 27, 2007; 104(9): 3432 - 3437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Jonstrup, J. Koch, and J. Kjems A microRNA detection system based on padlock probes and rolling circle amplification RNA, September 1, 2006; 12(9): 1747 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Cummins, Y. He, R. J. Leary, R. Pagliarini, L. A. Diaz Jr., T. Sjoblom, O. Barad, Z. Bentwich, A. E. Szafranska, E. Labourier, et al. The colorectal microRNAome PNAS, March 7, 2006; 103(10): 3687 - 3692. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CT 
